Neurology Central

DIAN-TU: solanezumab and gantenerumab yield disappointing results for rare form of Alzheimer’s


An initial analysis of the Dominantly Inherited Alzheimer’s Network-Trials Unit (DIAN-TU) has revealed that solanezumab and gantenerumab did not slow memory loss or cognitive decline in people with autosomal dominant Alzheimer’s disease.

The Phase II/III international trial indicated that neither drug met the primary outcome of the study (i.e., slowing of cognitive decline as measured by multiple tests of thinking and memory).

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.